CHA ALBERT

Average Profitability
29.43%
Insider Buys Quantity
10
Insider Buys Sum
$70.46M
Insider Sells Quantity
1
Insider Sells Sum
$189,050.40

Insider Activity of CHA ALBERT

The largest purchase of all time was on 2018-09-10 and amounted to 2117648 shares of KalVista Pharmaceuticals, Inc. for $36M.

The largest sale of all time was on 2023-09-11 and amounted to 18000 shares of KalVista Pharmaceuticals, Inc. for $189,050.

Biography of CHA ALBERT

No biography is available at this moment.

2023-09-11SaleKalVista Pharmaceuticals, Inc.
KALV
director
18,000
0.0521%
$10.50$189,050+12.43%
2020-10-30PurchaseKalVista Pharmaceuticals, Inc.
KALV
director
115,686
0.647%
$17.24$1.99M+18.83%
2019-07-29PurchaseKalVista Pharmaceuticals, Inc.
KALV
director
29,867
0.1734%
$17.13$511,702-27.21%
2019-07-26PurchaseKalVista Pharmaceuticals, Inc.
KALV
director
26,500
0.1507%
$16.83$446,035-26.89%
2019-07-19PurchaseKalVista Pharmaceuticals, Inc.
KALV
director
60,000
0.3481%
$17.81$1.07M-29.4%
2019-07-17PurchaseKalVista Pharmaceuticals, Inc.
KALV
director
1,280
0.0072%
$16.96$21,715-28.47%
2018-09-10PurchaseKalVista Pharmaceuticals, Inc.
KALV
director
2.12M
14.0828%
$17.00$36M+17.02%
2018-01-25PurchaseVYNE Therapeutics Inc.
VYNE
director
588,236
1.9809%
$17.00$10M-71.72%
2015-10-13PurchaseAclaris Therapeutics, Inc.
ACRS
director
909,090
4.5006%
$11.00$10M+61.56%
2015-10-07PurchaseAclaris Therapeutics, Inc.
ACRS
director
26,704
0.1491%
$11.00$293,744+81.54%
2015-04-14PurchaseKalVista Pharmaceuticals, Inc.
KALV
director
2.02M
7.8161%
$5.00$10.13M-23.08%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.